首页> 美国卫生研究院文献>Acta Crystallographica Section F: Structural Biology and Crystallization Communications >Crystallographic insights into the structure–activity relationships of diazaborine enoyl-ACP reductase inhibitors
【2h】

Crystallographic insights into the structure–activity relationships of diazaborine enoyl-ACP reductase inhibitors

机译:结晶学上对重氮唑啉烯酸-ACP还原酶抑制剂的构效关系的见解

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Enoyl-ACP reductase, the last enzyme of the fatty-acid biosynthetic pathway, is the molecular target for several successful antibiotics such as the tuberculosis therapeutic isoniazid. It is currently under investigation as a narrow-spectrum antibiotic target for the treatment of several types of bacterial infections. The diazaborine family is a group of boron heterocycle-based synthetic antibacterial inhibitors known to target enoyl-ACP reductase. Development of this class of molecules has thus far focused solely on the sulfonyl-containing versions. Here, the requirement for the sulfonyl group in the diazaborine scaffold was investigated by examining several recently characterized enoyl-ACP reductase inhibitors that lack the sulfonyl group and exhibit additional variability in substitutions, size and flexibility. Biochemical studies are reported showing the inhibition of Escherichia coli enoyl-ACP reductase by four diazaborines, and the crystal structures of two of the inhibitors bound to E. coli enoyl-ACP reductase solved to 2.07 and 2.11 Å resolution are reported. The results show that the sulfonyl group can be replaced with an amide or thioamide without disruption of the mode of inhibition of the molecule.
机译:Enoyl-ACP还原酶是脂肪酸生物合成途径的最后一种酶,是几种成功的抗生素(例如结核病治疗异烟肼)的分子靶标。目前,它正在作为一种窄谱抗生素靶标进行研究,用于治疗几种类型的细菌感染。 diazaborine家族是一组基于硼杂环的合成抗菌抑制剂,已知其靶向烯酰-ACP还原酶。迄今为止,这类分子的开发仅集中在含磺酰基的形式上。在这里,通过研究几种最近表征的缺乏磺酰基基团的烯酰基-ACP还原酶抑制剂,研究了重氮唑啉骨架中对磺酰基基团的需求。据生化研究报道,四种重氮唑嘌呤抑制了大肠杆菌的烯酰-ACP还原酶,并报道了两种与大肠杆菌的烯酰-ACP还原酶结合的抑制剂的晶体结构,其分辨率分别为2.07和2.11Å。结果表明,磺酰基可被酰胺或硫代酰胺取代而不破坏分子的抑制方式。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号